SKP2 and melanoma: Recently, Vemurafenib was reported to inhibit growth of BRAFV600E human melanoma cells, by the mechanisms that inhibition of BRAFV600E suppresses the expression level of c-Myc transcription factor, which binds to the E-box region on SKP2 promoter and regulates the Skp2 expression transcriptionally, dictating cell survival finally.